Treatment with PPARγ inhibitors in an in vitro OSCC model resulted in a substantial increase in the number and proportion of cDCs and CD8+ T cells in tumor tissue, leading to a significant inhibition of tumor growth. The gene discussed is CD8A; the disease is neoplasm.